Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Times, WSJ and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 77d ago.
Quick answers
Why is "Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn The Times · 91d ago
- Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion WSJ · 91d ago
- Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market Fierce Biotech · 91d ago
Topics
Related trends
Probing the many benefits of GLP-1 receptor agonists
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.